HR 6344 RDS
Office of Counternarcotics Enforcement to 
carry out its responsibilities under section 
878 of the Homeland Security Act of 2002 
(6 U.S.C. 458).’’; 
(3) in subparagraph (D)(iii), as so redesig-
nated, by inserting ‘‘and the appropriate congres-
sional committees’’ after ‘‘House of Representa-
tives’’; and 
(4) in subparagraph (E)(ii)(II)(bb), as so redes-
ignated, by inserting ‘‘and the appropriate congres-
sional committees’’ after ‘‘House of Representa-
tives’’. 
(d) REPROGRAMMING AND TRANSFER REQUESTS.— 
Section 704(c)(4)(A) (21 U.S.C. 1703(c)(4)(A)) is amend-
ed— 
(1) by striking ‘‘$5,000,000’’ and inserting 
‘‘$1,000,000’’; and 
(2) adding at the end the following: ‘‘If the Di-
rector has not responded to a request for reprogram-
ming subject to this subparagraph within 30 days 
after receiving notice of the request having been 
made, the request shall be deemed approved by the 
Director under this subparagraph and forwarded to 
Congress.’’. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
(e) POWERS
OF
DIRECTOR.—Section 704(d) is 
amended— 
(1) in paragraph (8)(D), by striking ‘‘have been 
authorized by Congress;’’ and inserting ‘‘authorized 
by law;’’; 
(2) in paragraph (9), by striking ‘‘Strategy; 
and’’ and inserting ‘‘Strategy and notify the appro-
priate congressional committees of any fund control 
notice issued; and’’; and 
(3) in paragraph (10), by striking ‘‘(22 U.S.C. 
2291j).’’ and inserting ‘‘(22 U.S.C. 2291j) and sec-
tion 706 of the Foreign Relations Authorization Act, 
Fiscal Year 2003 (22 U.S.C. 2291j–1).’’. 
(f) FUND CONTROL NOTICES.—Section 704(f) (21 
U.S.C. 1703(f)) is amended by adding at the end the fol-
lowing: 
‘‘(4) CONGRESSIONAL NOTICE.—A copy of each 
fund control notice shall be transmitted to the ap-
propriate congressional committees. 
‘‘(5) RESTRICTIONS.—The Director shall not 
issue a fund control notice to direct that all or part 
of an amount appropriated to the National Drug 
Control Program agency account be obligated, modi-
fied, or altered in any manner contrary, in whole or 
in part, to a specific appropriation or statute.’’. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00031
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
TITLE II—THE NATIONAL DRUG 
CONTROL STRATEGY 
SEC. 201. ANNUAL PREPARATION AND SUBMISSION OF NA-
TIONAL DRUG CONTROL STRATEGY. 
Section 706 is amended to read as follows: 
‘‘SEC. 706. DEVELOPMENT, SUBMISSION, IMPLEMENTATION, 
AND ASSESSMENT OF NATIONAL DRUG CON-
TROL STRATEGY. 
‘‘(a) TIMING, CONTENTS, AND PROCESS FOR DEVEL-
OPMENT AND SUBMISSION OF NATIONAL DRUG CONTROL 
STRATEGY.— 
‘‘(1) TIMING.—Not later than February 1 of 
each year, the President shall submit to Congress a 
National Drug Control Strategy, which shall set 
forth a comprehensive plan for the year to reduce il-
licit drug use and the consequences of such illicit 
drug use in the United States by limiting the avail-
ability of, and reducing the demand for, illegal 
drugs. 
‘‘(2) CONTENTS.— 
‘‘(A) IN
GENERAL.—The National Drug 
Control Strategy submitted under paragraph 
(1) shall include the following: 
‘‘(i) Comprehensive, research-based, 
long-range, quantifiable goals for reducing 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00032
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
illicit drug use and the consequences of il-
licit drug use in the United States. 
‘‘(ii) Annual quantifiable and measur-
able objectives and specific targets to ac-
complish long-term quantifiable goals that 
the Director determines may be achieved 
during each year beginning on the date on 
which the National Drug Control Strategy 
is submitted. 
‘‘(iii) A 5-year projection for program 
and budget priorities. 
‘‘(iv) A review of international, State, 
local, and private sector drug control ac-
tivities to ensure that the United States 
pursues coordinated and effective drug 
control at all levels of government. 
‘‘(v) An assessment of current illicit 
drug use (including inhalants and steroids) 
and availability, impact of illicit drug use, 
and treatment availability, which assess-
ment shall include— 
‘‘(I) estimates of drug prevalence 
and frequency of use as measured by 
national, State, and local surveys of il-
licit drug use and by other special 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00033
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
studies of nondependent and depend-
ent illicit drug use; 
‘‘(II) illicit drug use in the work-
place and the productivity lost by such 
use; and 
‘‘(III) 
illicit 
drug 
use 
by 
arrestees, probationers, and parolees. 
‘‘(vi) An assessment of the reduction 
of illicit drug availability, as measured 
by— 
‘‘(I) the quantities of cocaine, 
heroin, marijuana, methamphetamine, 
ecstasy, and other drugs available for 
consumption in the United States; 
‘‘(II) the amount of marijuana, 
cocaine, heroin, methamphetamine, ec-
stasy, and precursor chemicals and 
other drugs entering the United 
States; 
‘‘(III) the number of illicit drug 
manufacturing laboratories seized and 
destroyed and the number of hectares 
of marijuana, poppy, and coca cul-
tivated and destroyed domestically 
and in other countries; 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00034
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(IV) the number of metric tons 
of marijuana, heroin, cocaine, and 
methamphetamine seized and other 
drugs; and 
‘‘(V) changes in the price and 
purity of heroin, methamphetamine, 
and cocaine, changes in the price of 
ecstasy, 
and 
changes 
in 
tetrahydrocannabinol level of mari-
juana and other drugs. 
‘‘(vii) An assessment of the reduction 
of the consequences of illicit drug use and 
availability, which shall include— 
‘‘(I) the burden illicit drug users 
placed on hospital emergency depart-
ments in the United States, such as 
the quantity of illicit drug-related 
services provided; 
‘‘(II) the annual national health 
care cost of illicit drug use; and 
‘‘(III) the extent of illicit drug- 
related crime and criminal activity. 
‘‘(viii) A determination of the status 
of drug treatment in the United States, by 
assessing— 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00035
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(I) public and private treatment 
utilization; and 
‘‘(II) the number of illicit drug 
users the Director estimates meet di-
agnostic criteria for treatment. 
‘‘(ix) A review of the research agenda 
of the Counterdrug Technology Assessment 
Center to reduce the availability and abuse 
of drugs. 
‘‘(x) A summary of the efforts made 
to coordinate with private sector entities to 
conduct private research and development 
of medications to treat addiction by— 
‘‘(I) screening chemicals for po-
tential therapeutic value; 
‘‘(II) developing promising com-
pounds; 
‘‘(III) conducting clinical trials; 
‘‘(IV) seeking Food and Drug 
Administration approval for drugs to 
treat addiction; 
‘‘(V) marketing the drug for the 
treatment of addiction; 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00036
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(VI) urging physicians to use 
the drug in the treatment of addic-
tion; and 
‘‘(VII) 
encouraging 
insurance 
companies to reimburse the cost of 
the drug for the treatment of addic-
tion. 
‘‘(xi) An assessment of Federal effec-
tiveness in achieving the National Drug 
Control Strategy for the previous year, in-
cluding a specific evaluation of whether the 
objectives and targets for reducing illicit 
drug use for the previous year were met 
and reasons for the success or failure of 
the previous year’s Strategy. 
‘‘(xii) A general review of the status 
of, and trends in, demand reduction activi-
ties by private sector entities and commu-
nity-based organizations, including faith- 
based organizations, to determine their ef-
fectiveness and the extent of cooperation, 
coordination, and mutual support between 
such entities and organizations and Fed-
eral, State, local, and tribal government 
agencies. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00037
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(xiii) Such additional statistical data 
and information as the Director considers 
appropriate to demonstrate and assess 
trends relating to illicit drug use, the ef-
fects and consequences of illicit drug use 
(including the effects on children of sub-
stance abusers), supply reduction, demand 
reduction, drug-related law enforcement, 
and the implementation of the National 
Drug Control Strategy. 
‘‘(xiv) A supplement reviewing the ac-
tivities of each individual National Drug 
Control Program agency during the pre-
vious year with respect to the National 
Drug Control Strategy and the Director’s 
assessment of the progress of each Na-
tional Drug Control Program agency in 
meeting its responsibilities under the Na-
tional Drug Control Strategy. 
‘‘(B) 
CLASSIFIED
INFORMATION.—Any 
contents of the National Drug Control Strategy 
that involve information properly classified 
under criteria established by an Executive order 
shall be presented to Congress separately from 
the rest of the National Drug Control Strategy. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00038
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(C) SELECTION OF DATA AND INFORMA-
TION.—In selecting data and information for 
inclusion under subparagraph (A), the Director 
shall ensure— 
‘‘(i) the inclusion of data and informa-
tion that will permit analysis of current 
trends against previously compiled data 
and information where the Director be-
lieves such analysis enhances long-term as-
sessment of the National Drug Control 
Strategy; and 
‘‘(ii) the inclusion of data and infor-
mation to permit a standardized and uni-
form assessment of the effectiveness of 
drug treatment programs in the United 
States. 
‘‘(3) PROCESS FOR DEVELOPMENT AND SUB-
MISSION.—In developing and effectively imple-
menting the National Drug Control Strategy, the 
Director— 
‘‘(A) shall consult with— 
‘‘(i) the heads of the National Drug 
Control Program agencies; 
‘‘(ii) Congress; 
‘‘(iii) State, local, and tribal officials; 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00039
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(iv) private citizens and organiza-
tions, including community and faith-based 
organizations with experience and expertise 
in demand reduction; 
‘‘(v) private citizens and organizations 
with experience and expertise in supply re-
duction; and 
‘‘(vi) appropriate representatives of 
foreign governments; 
‘‘(B) in satisfying the requirements of sub-
paragraph (A), shall ensure, to the maximum 
extent possible, that State, local, and tribal offi-
cials and relevant private organizations commit 
to support and take steps to achieve the goals 
and objectives of the National Drug Control 
Strategy; 
‘‘(C) with the concurrence of the Attorney 
General, may require the El Paso Intelligence 
Center to undertake specific tasks or projects to 
support or implement the National Drug Con-
trol Strategy; and 
‘‘(D) with the concurrence of the Director 
of National Intelligence and the Attorney Gen-
eral, may request that the National Drug Intel-
ligence Center undertake specific tasks or 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00040
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
projects to support or implement the National 
Drug Control Strategy. 
‘‘(b) SUBMISSION
OF REVISED STRATEGY.—The 
President may submit to Congress a revised National 
Drug Control Strategy that meets the requirements of this 
section— 
‘‘(1) at any time, upon a determination of the 
President, in consultation with the Director, that the 
National Drug Control Strategy in effect is not suf-
ficiently effective; or 
‘‘(2) if a new President or Director takes of-
fice.’’. 
SEC. 202. PERFORMANCE MEASUREMENTS. 
Section 706 is amended by adding at the end the fol-
lowing: 
‘‘(c) PERFORMANCE MEASUREMENT SYSTEM.—Not 
later than February 1 of each year, the Director shall sub-
mit to Congress as part of the National Drug Control 
Strategy, a description of a national drug control perform-
ance measurement system, that— 
‘‘(1) develops 2-year and 5-year performance 
measures and targets for each National Drug Con-
trol Strategy goal and objective established for re-
ducing drug use, availability, and the consequences 
of drug use; 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00041
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(2) describes the sources of information and 
data that will be used for each performance measure 
incorporated into the performance measurement sys-
tem; 
‘‘(3) identifies major programs and activities of 
the National Drug Control Program agencies that 
support the goals and annual objectives of the Na-
tional Drug Control Strategy; 
‘‘(4) evaluates the contribution of demand re-
duction and supply reduction activities as defined in 
section 702 implemented by each National Drug 
Control Program agency in support of the National 
Drug Control Strategy; 
‘‘(5) monitors consistency between the drug-re-
lated goals and objectives of the National Drug Con-
trol Program agencies and ensures that each agen-
cy’s goals and budgets support and are fully con-
sistent with the National Drug Control Strategy; 
and 
‘‘(6) coordinates the development and imple-
mentation of national drug control data collection 
and reporting systems to support policy formulation 
and performance measurement, including an assess-
ment of— 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00042
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS
HR 6344 RDS
‘‘(A) the quality of current drug use meas-
urement instruments and techniques to measure 
supply reduction and demand reduction activi-
ties; 
‘‘(B) the adequacy of the coverage of exist-
ing national drug use measurement instruments 
and techniques to measure the illicit drug user 
population, and groups that are at risk for il-
licit drug use; 
‘‘(C) the adequacy of the coverage of exist-
ing national treatment outcome monitoring sys-
tems to measure the effectiveness of drug abuse 
treatment in reducing illicit drug use and crimi-
nal behavior during and after the completion of 
substance abuse treatment; and 
‘‘(D) the actions the Director shall take to 
correct any deficiencies and limitations identi-
fied pursuant to subparagraphs (A) and (B) of 
this subsection. 
‘‘(d) MODIFICATIONS.—A description of any modi-
fications made during the preceding year to the national 
drug performance measurement system described in sub-
section (c) shall be included in each report submitted 
under subsection (b).’’. 
VerDate Aug 31 2005 
23:24 Dec 12, 2006
Jkt 059200
PO 00000
Frm 00043
Fmt 6652
Sfmt 6201
E:\BILLS\H6344.RDS
H6344
pwalker on PRODPC60 with BILLS